Loading institutional data...
Loading institutional data...
Strong institutional distribution: ownership decreased -89.09% quarter-over-quarter.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
A reverse discounted cash flow is not shown for an insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Classified from the filings: SIC code.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-11-02 | Smith Henry B Director | Open-market sale | 4,893 | $106.15 | $519k |
| 2026-11-01 | Kirk Matthew CFO | Tax withholding | 1,063 | $104.87 | $111k |
| 2026-06-01 | 3 co-filers President and CEO | Tax withholding | 31,029 | $95.90 | $3.0m |
| 2026-06-01 | 3 co-filers President and CEO | Tax withholding | 2,586 | $95.90 | $248k |
| 2026-05-13 | 3 co-filers President and CEO | Grant16d late | 60,662 | $0.00 | $0 |
| 2026-05-07 | Smith Henry B Director | Open-market sale | 2,542 | $98.69 | $251k |
| 2026-03-01 | 2 co-filers President and CEO | Tax withholding | 10,557 | $105.72 | $1.1m |
| 2026-03-01 | 2 co-filers Chief Admin and Legal Officer | Tax withholding | 3,983 | $105.72 | $421k |
| 2026-03-01 | 2 co-filers Chief Investment Officer | Tax withholding | 9,511 | $105.72 | $1.0m |
| 2026-03-01 | 2 co-filers CFO | Tax withholding | 8,768 | $105.72 | $927k |
| 2026-03-01 | 2 co-filers Grp Chief Underwriting Officer | Tax withholding | 2,586 | $105.72 | $273k |
| 2026-03-01 | 2 co-filers President and CEO | Tax withholding | 8,828 | $105.72 | $933k |
| 2026-03-01 | 2 co-filers Chief Investment Officer | Tax withholding | 4,816 | $105.72 | $509k |
| 2026-03-01 | 2 co-filers Chief Admin and Legal Officer | Tax withholding | 3,303 | $105.72 | $349k |
| 2026-03-01 | 2 co-filers CFO | Tax withholding | 4,378 | $105.72 | $463k |
| 2026-03-01 | 2 co-filers Grp Chief Underwriting Officer | Tax withholding | 2,941 | $105.72 | $311k |
| 2026-01-28 | 2 co-filers CFO | Grant | 20,638 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers Chief Investment Officer | Grant | 5,853 | $0.00 | $0 |
| 2026-01-27 | Bolovinos Athanasios Tom Principal Acct Off | Grant | 2,828 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers Grp Chief Underwriting Officer | Grant | 6,438 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers President and CEO | Grant | 37,069 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers CFO | Grant | 13,657 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers Chief Admin and Legal Officer | Grant | 4,682 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers President and CEO | Grant | 20,638 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers Chief Admin and Legal Officer | Grant | 8,942 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers Grp Chief Underwriting Officer | Grant | 5,502 | $0.00 | $0 |
| 2026-01-27 | 2 co-filers Chief Investment Officer | Grant | 17,198 | $0.00 | $0 |
| 2026-01-15 | Zlatkus Lizabeth H Director | Grant | 1,843 | — | — |
| 2026-01-15 | Becker W Marston Director | Grant | 2,840 | — | — |
| 2026-01-15 | Davis Charles A Director | Grant | 2,840 | — | — |
| 2026-01-15 | Dowling Anne Melissa Director | Grant | 1,594 | — | — |
| 2026-01-15 | Galanski Stanley A Director | Grant | 1,594 | — | — |
| 2026-01-15 | Hardwick Elanor Director | Grant | 1,594 | — | — |
| 2026-01-15 | Millegan Michael Director | Grant | 1,594 | — | — |
| 2026-01-15 | Ramey Thomas C. Director | Grant | 1,594 | — | — |
| 2026-01-15 | Smith Henry B Director | Grant | 1,594 | — | — |
| 2026-01-15 | Theis Axel Director | Grant | 1,594 | — | — |
| 2026-01-15 | Yastine Barbara A. Director | Grant | 1,594 | — | — |
| 2025-12-02 | Bolovinos Athanasios Tom Principal Acct Off | Grant | 2,263 | $0.00 | $0 |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $142.7M dividends + $887.7M buybacks = $1.03B returned on -$92.2M FCF.
7 consecutive years of dividend increases · 3%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 16%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
No current price collected.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 16% against ROIC 16% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| SG&A | 12.3 | 12.3 | 12.0 | 12.5 | 13.2 | 12.1 | 11.2 | 10.7 |
| Income Tax | -0.6 | 0.5 | -0.3 | 1.2 | 0.4 | 0.5 | -0.9 | 3.3 |
| Net Income | 0.8 | 6.3 | -2.5 | 11.6 | 4.3 | 6.7 | 18.2 | 15.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on AXS-PE: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Leverage ratios is not shown for an insurer.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Classified from the filings: SIC code.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $820.3M covers the $0 due within a year 820252000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | not reported | not reported | 12.8% |
| FY2017 | not reported | not reported | -8.0% |
| FY2018 | not reported | not reported | 0.8% |
| FY2019 | not reported | not reported | 6.3% |
| FY2020 | not reported | not reported | -2.5% |
| FY2021 | not reported | not reported | 11.6% |
| FY2022 | not reported | not reported | 4.3% |
| FY2023 | not reported | not reported | 6.7% |
| FY2024 | not reported | not reported | 18.2% |
| FY2025 | not reported | not reported | 15.4% |
Return on equity (16%) and return on invested capital (16%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: beta, market_cap.
Converts 2.03x of reported profit into cash — adequate, without much margin.
Reported free cash flow is -$92M; after share-based compensation it is -$137M. The difference is a real cost that the cash flow statement adds back.
Leverage is not measurable this way for a insurer.
Ladder as of 2025-12-31 (10-K); cash from the 2025-12-31 balance sheet; FCF from FY2025. Free cash flow is negative, so projected resources fall rather than accumulate.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Funded by policyholder float, not debt. Reserve adequacy and RBC are the right questions and are not collected yet.
Missing from our data, so excluded from this answer: capital adequacy metrics for this archetype.
No current price or share count, so the market's assumption cannot be solved for.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: market_cap.
| Step | Amount | Running total |
|---|---|---|
| Net income | $1.01B | $1.01B |
| Share-based comp | $45M | $1.05B |
| Other non-cash & working capital | −$1.10B | −$41M |
| Operating cash flow | −$41M | −$41M |
| Capex | −$51M | −$92M |
| Free cash flow | −$92M | −$92M |
| FCF after SBC | −$137M | −$137M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -6.4% | not reported | not reported |
| FY2021 | 9.9% | not reported | not reported |
| FY2022 | -3.5% | not reported | not reported |
| FY2023 | 9.9% | not reported | not reported |
| FY2024 | 5.6% | not reported | not reported |
| FY2025 | 10.2% | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | 0.5 percent |
| FY2020 | -1.8 percent |
| FY2021 | -2.1 percent |
| FY2022 | -2.1 percent |
| FY2023 | -2.9 percent |
| FY2024 | -2.3 percent |
| FY2025 | 3.0 percent |
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it. This year they exceeded net income, so the ribbons are capped at earnings and understate what was actually returned.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.56B 100.0% | $5.96B 100.0% | $5.64B 100.0% | $5.14B 100.0% | $5.32B 100.0% | $4.84B 100.0% | $5.17B 100.0% | $5.09B 100.0% | $4.59B 100.0% | $4.01B 100.0% |
| Selling, General & Admin | $703.9M 10.7% | $666.2M 11.2% | $684.4M 12.1% | $680.3M 13.2% | $663.3M 12.5% | $579.8M 12.0% | $634.8M 12.3% | $627.4M 12.3% | $579.4M 12.6% | $602.7M 15.0% |
| Interest Expense | $66.7M 1.0% | $67.8M 1.1% | $68.4M 1.2% | $63.1M 1.2% | $62.3M 1.2% | $75.0M 1.5% | $68.1M 1.3% | $67.4M 1.3% | $54.8M 1.2% | $51.4M 1.3% |
| Pretax Income | $1.23B 18.7% | $1.03B 17.2% | $402.6M 7.1% | $245.1M 4.8% | $681.0M 12.8% | -$132.7M -2.7% | $347.2M 6.7% | $13.5M 0.3% | -$376.5M -8.2% | $519.7M 13.0% |
| Income Tax Expense | $216.7M 3.3% | -$55.6M -0.9% | $26.3M 0.5% | $22.0M 0.4% | $62.4M 1.2% | -$12.3M -0.3% | $23.7M 0.5% | -$29.5M -0.6% | -$7.5M -0.2% | $6.3M 0.2% |
| Net Income | $1.01B 15.4% | $1.08B 18.2% | $376.3M 6.7% | $223.1M 4.3% | $618.6M 11.6% | -$120.4M -2.5% | $323.5M 6.3% | $43.0M 0.8% | -$369.0M -8.0% | $513.4M 12.8% |
| Per Share | ||||||||||
| EPS (Basic) | $12.52 | $12.49 | $4.06 | $2.27 | $6.95 | -$1.79 | $3.37 | $0.00 | -$4.94 | $5.13 |
| EPS (Diluted) | $12.35 | $12.35 | $4.02 | $2.25 | $6.90 | -$1.79 | $3.34 | $0.00 | -$4.94 | $5.08 |
| Weighted Avg Shares (Basic) | 78.2M | 84.2M | 85.1M | 84.9M | 84.7M | 84.3M | 83.9M | 83.5M | 84.1M | 90.8M |
| Weighted Avg Shares (Diluted) | 79.3M | 85.2M | 86.0M | 85.7M | 85.3M | 84.3M | 84.5M | 84.0M | 84.1M | 91.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.